Sage Therapeutics (NASDAQ:SAGE) Releases Earnings Results, Misses Expectations By $0.02 EPS

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) released its earnings results on Tuesday. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02), Zacks reports. The company had revenue of $14.06 million during the quarter, compared to analyst estimates of $14.12 million. Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The firm's revenue for the quarter was up 78.0% on a year-over-year basis. During the same quarter last year, the business earned ($1.80) earnings per share.

Sage Therapeutics Stock Performance

Shares of SAGE stock traded down $0.18 on Friday, hitting $7.30. 1,060,063 shares of the stock traded hands, compared to its average volume of 1,221,130. The firm's 50-day moving average price is $7.54 and its two-hundred day moving average price is $6.78. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $14.31. The stock has a market capitalization of $457.13 million, a PE ratio of -1.11 and a beta of 0.20.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Canaccord Genuity Group reduced their target price on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a research note on Wednesday, February 12th. StockNews.com raised Sage Therapeutics from a "sell" rating to a "hold" rating in a report on Friday. Scotiabank cut their price target on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a report on Wednesday, February 12th. Bank of America began coverage on shares of Sage Therapeutics in a research note on Tuesday, March 11th. They issued an "underperform" rating and a $5.00 price objective on the stock. Finally, Needham & Company LLC restated a "hold" rating on shares of Sage Therapeutics in a research report on Friday, April 25th. Two analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $8.81.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.